期刊
CELL CHEMICAL BIOLOGY
卷 25, 期 7, 页码 849-+出版社
CELL PRESS
DOI: 10.1016/j.chembiol.2018.04.007
关键词
-
资金
- University of Copenhagen
- Carlsberg Foundation [2011_01_0169, 2013_01_0333, CF15-0115]
- Novo Nordisk Foundation [NNF15OC0017334]
- European Research Council [ERC-CoG-725172]
Histone deacetylase (HDAC) enzymes regulate diverse biological function, including gene expression, rendering them potential targets for intervention in a number of diseases, with a handful of compounds approved for treatment of certain hematologic cancers. Among the human zinc-dependent HDACs, the most recently discovered member, HDAC11, is the only member assigned to subclass IV. It is the smallest protein and has the least well understood biological function. Here, we show that HDAC11 cleaves long-chain acyl modifications on lysine side chains with remarkable efficiency. We further show that several common types of HDAC inhibitors, including the approved drugs romidepsin and vorinostat, do not inhibit this enzymatic activity. Macrocyclic hydroxamic acid-containing peptides, on the other hand, potently inhibit HDAC11 demyris-toylation activity. These findings should be taken carefully into consideration in future investigations of the biological function of HDAC11 and will serve as a foundation for the development of selective chemical probes targeting HDAC11.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据